Retour
Prix Agenus Inc (AGEN)
Graphique du cours de l'action AGEN
AGEN Gagner
Agenus Inc
$2.92
2.45%
$0.06
À la fermeture : Feb 13, 16:00:00 GMT-5
$2.87
-1.71%
$-0.04
Post-Marché: Feb 13, 20:00:00 GMT-5
Derniers résultats des bénéfices : Q3 '25
Signalé : 2025-11-10
Bénéfices historiques
Trimestriellement
Annuel
EPS
Revenus
Earnings FAQ
Comment le bénéfice par action récent de AGEN se compare-t-il aux attentes ?
Comment les revenus de Agenus Inc AGEN se sont-ils comportés au dernier trimestre ?
Quelle est l'estimation des revenus pour Agenus Inc ?
Quel est le score de qualité des bénéfices pour Agenus Inc ?
Quand Agenus Inc publie-t-elle ses résultats ?
Quels sont les bénéfices attendus de Agenus Inc ?
Agenus Inc a-t-elle dépassé les attentes en matière de bénéfices ?
Statistiques clés
Clôture préc.
$2.85
Prix d'ouverture
$2.86
Plage de la journée
$2.83 - $3.01
Plage de 52 semaines
$1.38 - $7.34
Volume
272.2K
Volume moyen
663.2K
BPA (TTM)
-2.84
Rendement en dividend
--
Capitalisation boursière
$97.6M
Qu’est-ce que AGEN ?
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 316 full-time employees. The company went IPO on 2000-02-04. The firm is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The firm has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Fonctionnalités
Ressources
© 2026 Finture Development Limited. Tous droits réservés.